IT’S TRU.
Learn more atkeytruda.comKaty is a real patient.The immunotherapy with the most FDA-approved uses for advanced lung cancer
Half of the patients receiving KEYTRUDA with chemotherapy were alive without their cancer spreading, growing, or getting
worse at 8.8 months compared with 4.9 months for patients receiving chemotherapy alone. Cancer did not progress in
40% of patients receiving KEYTRUDA with chemotherapy compared with 19% of patients receiving chemotherapy alone.
IMPORTANT SAFETY INFORMATION (continued)
- Rejection of a transplanted organ. People who have
had an organ transplant may have an increased risk
of organ transplant rejection if they are treated with
KEYTRUDA. - Complications, including graft-versus-host disease
(GVHD), in people who have received a bone
marrow (stem cell) transplant that uses donor
stem cells (allogeneic). These complications can be
severe and can lead to death. These complications
may happen if you underwent transplantation either
before or after being treated with KEYTRUDA. Your
doctor will monitor you for the following signs and
symptoms: skin rash, liver infl ammation, abdominal
pain, and diarrhea.
Getting medical treatment right away may help keep
these problems from becoming more serious. Your
doctor will check you for these problems during
treatment with KEYTRUDA. Your doctor may treat you
with corticosteroid or hormone replacement medicines.
Your doctor may also need to delay or completely
stop treatment with KEYTRUDA if you have severe
side effects.
Before you receive KEYTRUDA, tell your doctor if
you have immune system problems such as Crohn’s
disease, ulcerative colitis, or lupus; have had an organ
transplant or plan to have or have had a bone marrow
(stem cell) transplant that used donor stem cells
(allogeneic); have lung or breathing problems; have
liver problems; or have any other medical problems.
If you are pregnant or plan to become pregnant, tell your
doctor. KEYTRUDA can harm your unborn baby. If you are
able to become pregnant, your doctor will give you a
pregnancy test before you start treatment. Use effective
birth control during treatment and for at least 4 months
after the fi nal dose of KEYTRUDA. Tell your doctor right
away if you think you may be pregnant or you become
pregnant during treatment with KEYTRUDA.
If you are breastfeeding or plan to breastfeed, tell your
doctor. It is not known if KEYTRUDA passes into your
breast milk. Do not breastfeed during treatment with
KEYTRUDA and for 4 months after your fi nal dose of
KEYTRUDA.
Tell your doctor about all the medicines you take,
including prescription and over-the-counter medicines,
vitamins, and herbal supplements.
Common side effects of KEYTRUDA when given with
certain chemotherapy medicines include feeling tired
or weak; nausea; constipation; diarrhea; decreased
appetite; rash; vomiting; cough; trouble breathing;
fever; hair loss; infl ammation of the nerves that may
cause pain, weakness, and paralysis in the arms and
legs; swelling of the lining of the mouth, nose, eyes,
throat, intestines, or vagina; and mouth sores.
These are not all the possible side effects of KEYTRUDA.
Tell your doctor if you have any side effect that bothers
you or that does not go away. For more information, ask
your doctor or pharmacist.
Please read the adjacent Important Information
About KEYTRUDA and discuss it with your oncologist.
You are encouraged to report negative side effects of
prescription drugs to the FDA. Visit http://www.fda.gov/
medwatch or call 1-800-FDA-1088.
Having trouble paying for your Merck medicine?
Merck may be able to help. http://www.merckhelps.comCopyright © 2019 Merck Sharp & Dohme Corp.,
a subsidiary of Merck & Co., Inc.
All rights reserved.
US-LAM-00406 07/19